Bone grafts and bone morphogenetic proteins in spine fusion

Munish C. Gupta, Sukanta Maitra

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Spinal fusions are being performed for various pathologies of the spine. Stabilizing vertebral segments by eliminating motion across those segments becomes critical in dealing with pathologies of the spine that lead to instability. The use of autograft has been the gold standard for spine fusion. However, due to complications such as donor site morbidity, increased operating time, and limited supply, the use of allograft as a graft extender has become an acceptable practice especially in fusions spanning multiple segments. The discovery and isolation of novel proteins (i.e., bone morphogenetic proteins, BMPs), which initiate the molecular cascade of bone formation, have experimentally been shown in numerous animal studies to be as effective as autografts. Although the use of BMPs has exciting applications in spine surgery, long-term clinical studies must be evaluated for its efficacy in various applications in humans. The use of biomimetic materials such as hydroxyapatite (HA), or tricalcium phosphate (TCP) has also been examined in several animal models as bone graft substitutes or carriers. Although these materials have shown some promise in specific site applications, more work remains in elucidating an efficacious combination of these materials and BMPs that can be as effective as autografts. This review will present the status of bone grafts, bone morphogenetic proteins, gene therapy, and work that has been done to facilitate spinal fusion and simultaneously eliminate the need for bone graft.

Original languageEnglish (US)
Pages (from-to)255-267
Number of pages13
JournalCell and Tissue Banking
Volume3
Issue number4
DOIs
StatePublished - 2002

Fingerprint

Bone Morphogenetic Proteins
Grafts
Autografts
Bone
Spine
Fusion reactions
Proteins
Transplants
Bone and Bones
Spinal Fusion
Pathology
Biomimetic Materials
Animals
Biomimetic materials
Bone Substitutes
Gene therapy
Durapatite
Osteogenesis
Genetic Therapy
Surgery

Keywords

  • BMPs
  • Bone grafts
  • GDF-5
  • Hydroxyapatite
  • Spine fusion
  • Tricalcium phosphate

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Bone grafts and bone morphogenetic proteins in spine fusion. / Gupta, Munish C.; Maitra, Sukanta.

In: Cell and Tissue Banking, Vol. 3, No. 4, 2002, p. 255-267.

Research output: Contribution to journalArticle

Gupta, Munish C. ; Maitra, Sukanta. / Bone grafts and bone morphogenetic proteins in spine fusion. In: Cell and Tissue Banking. 2002 ; Vol. 3, No. 4. pp. 255-267.
@article{3068c070ee2648b4b4150972678de103,
title = "Bone grafts and bone morphogenetic proteins in spine fusion",
abstract = "Spinal fusions are being performed for various pathologies of the spine. Stabilizing vertebral segments by eliminating motion across those segments becomes critical in dealing with pathologies of the spine that lead to instability. The use of autograft has been the gold standard for spine fusion. However, due to complications such as donor site morbidity, increased operating time, and limited supply, the use of allograft as a graft extender has become an acceptable practice especially in fusions spanning multiple segments. The discovery and isolation of novel proteins (i.e., bone morphogenetic proteins, BMPs), which initiate the molecular cascade of bone formation, have experimentally been shown in numerous animal studies to be as effective as autografts. Although the use of BMPs has exciting applications in spine surgery, long-term clinical studies must be evaluated for its efficacy in various applications in humans. The use of biomimetic materials such as hydroxyapatite (HA), or tricalcium phosphate (TCP) has also been examined in several animal models as bone graft substitutes or carriers. Although these materials have shown some promise in specific site applications, more work remains in elucidating an efficacious combination of these materials and BMPs that can be as effective as autografts. This review will present the status of bone grafts, bone morphogenetic proteins, gene therapy, and work that has been done to facilitate spinal fusion and simultaneously eliminate the need for bone graft.",
keywords = "BMPs, Bone grafts, GDF-5, Hydroxyapatite, Spine fusion, Tricalcium phosphate",
author = "Gupta, {Munish C.} and Sukanta Maitra",
year = "2002",
doi = "10.1023/A:1024605128411",
language = "English (US)",
volume = "3",
pages = "255--267",
journal = "Cell and Tissue Banking",
issn = "1389-9333",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Bone grafts and bone morphogenetic proteins in spine fusion

AU - Gupta, Munish C.

AU - Maitra, Sukanta

PY - 2002

Y1 - 2002

N2 - Spinal fusions are being performed for various pathologies of the spine. Stabilizing vertebral segments by eliminating motion across those segments becomes critical in dealing with pathologies of the spine that lead to instability. The use of autograft has been the gold standard for spine fusion. However, due to complications such as donor site morbidity, increased operating time, and limited supply, the use of allograft as a graft extender has become an acceptable practice especially in fusions spanning multiple segments. The discovery and isolation of novel proteins (i.e., bone morphogenetic proteins, BMPs), which initiate the molecular cascade of bone formation, have experimentally been shown in numerous animal studies to be as effective as autografts. Although the use of BMPs has exciting applications in spine surgery, long-term clinical studies must be evaluated for its efficacy in various applications in humans. The use of biomimetic materials such as hydroxyapatite (HA), or tricalcium phosphate (TCP) has also been examined in several animal models as bone graft substitutes or carriers. Although these materials have shown some promise in specific site applications, more work remains in elucidating an efficacious combination of these materials and BMPs that can be as effective as autografts. This review will present the status of bone grafts, bone morphogenetic proteins, gene therapy, and work that has been done to facilitate spinal fusion and simultaneously eliminate the need for bone graft.

AB - Spinal fusions are being performed for various pathologies of the spine. Stabilizing vertebral segments by eliminating motion across those segments becomes critical in dealing with pathologies of the spine that lead to instability. The use of autograft has been the gold standard for spine fusion. However, due to complications such as donor site morbidity, increased operating time, and limited supply, the use of allograft as a graft extender has become an acceptable practice especially in fusions spanning multiple segments. The discovery and isolation of novel proteins (i.e., bone morphogenetic proteins, BMPs), which initiate the molecular cascade of bone formation, have experimentally been shown in numerous animal studies to be as effective as autografts. Although the use of BMPs has exciting applications in spine surgery, long-term clinical studies must be evaluated for its efficacy in various applications in humans. The use of biomimetic materials such as hydroxyapatite (HA), or tricalcium phosphate (TCP) has also been examined in several animal models as bone graft substitutes or carriers. Although these materials have shown some promise in specific site applications, more work remains in elucidating an efficacious combination of these materials and BMPs that can be as effective as autografts. This review will present the status of bone grafts, bone morphogenetic proteins, gene therapy, and work that has been done to facilitate spinal fusion and simultaneously eliminate the need for bone graft.

KW - BMPs

KW - Bone grafts

KW - GDF-5

KW - Hydroxyapatite

KW - Spine fusion

KW - Tricalcium phosphate

UR - http://www.scopus.com/inward/record.url?scp=0043130708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043130708&partnerID=8YFLogxK

U2 - 10.1023/A:1024605128411

DO - 10.1023/A:1024605128411

M3 - Article

VL - 3

SP - 255

EP - 267

JO - Cell and Tissue Banking

JF - Cell and Tissue Banking

SN - 1389-9333

IS - 4

ER -